ACHIEVEMENT OF REMISSION AS A MODERN PURPOSE OF ANTIDEPRESSANT THERAPY

Abstract

During the analysis of valdoxan (agomelatine) effectiveness in the treatment of depressive disorders (50 patients) clinical predictors of the most complete response to the point of remission are marked. Among patients who completed the study (40 patients), 36 were responders (90 %). The remission was seen in 27 patients of 40. Primary response after 1-2 weeks of therapy was defined as a prognostic factor of remission.

Keywords

• depressive disorder
• antidepressant therapy
• remission
• primary response
• valdoxan